HYTN Announces Sale and Distribution of GMP Cannabis Products in the UK

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or "the Company"), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its first international order for products manufactured under its recently awarded Good Manufacturing Practices (GMP) designation.

The completed shipment of this first order includes the successful export, import, final packaging and release for supply of 43.75 kilograms of cannabis flower for medical use. The company confirms that this initial order has been paid in full and that the products shipped are now available to patients across the UK through the country's regulated medical sales model.

Following this initial success, HYTN has received orders for immediate manufacture totaling over 500 kilograms of additional products, underscoring the growing demand for its premium cannabis-based pharmaceuticals in the international market.

"The fulfillment of our first order to 4C LABS and the subsequent substantial orders highlight the trust and confidence our partners place in our products and the strength and efficiency of our GMP standards," said Jason Broome, Chief Operations Officer of HYTN. "We are committed to stabilizing international supply lines and ensuring that our products meet or exceed the regulatory requirements of international markets."

HYTN's products are manufactured under Good Manufacturing Practices (GMP) standards, ensuring they meet the stringent quality requirements of international markets. This milestone aligns with HYTN's strategic goal to expand its global footprint and provide high-quality cannabis products to patients worldwide.

About HYTN Innovations Inc.

HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

About 4C LABS Ltd.

4C LABS is a Canadian-based Medical Cannabis company which is building a vertically integrated, quality-driven infrastructure for procuring and delivering premium medical cannabis products to the UK, EU and other international regulated markets.

4C LABS focuses on launching products in regulated markets with an additional focus on research and development of new and innovative plant based therapeutic finished product forms that can be introduced to the 4C catalogue.

About Good Manufacturing Practices

GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.